ANXA2‐mediated Phagocytosis Generates AR <sup>+</sup> Macrophages to Confer Enzalutamide Resistance in Prostate Cancer
TAMs, challenging the tumor-centric view of therapy failure and providing a strong rationale for co-targeting the IL-6 pathway to improve outcomes of AR-directed therapy in CRPC.
Authors
- Zonglin Li (ORCID: https://orcid.org/0000-0002-8949-9455)
- Hai Huang (ORCID: https://orcid.org/0000-0002-2013-073X)
- Shengmeng Peng (ORCID: https://orcid.org/0009-0004-8989-9215)
- Lingfeng Li (ORCID: https://orcid.org/0000-0001-9872-002X)
- Weilong Lin (ORCID: https://orcid.org/0009-0003-0663-1903)
- Bisheng Cheng (ORCID: https://orcid.org/0009-0005-2300-3583)
- Shanhe Huang (ORCID: https://orcid.org/0009-0007-5103-6475)
- Yuan Ou
- Tao Du
- Tianlong Luo
- Qi Sun
- Kewei Xu (ORCID: https://orcid.org/0000-0003-4649-4619)
- Dongquan Li
Institutions
- Beth Israel Deaconess Medical Center (US)
- University of British Columbia (CA)
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Sun Yat-sen Memorial Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Southern Medical University (CN)
- University of Hong Kong (HK)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2026-04-16
- DOI
- https://doi.org/10.1002/advs.75290
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation